CLINICAL TRIAL

Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use Disorder

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2026-07-09
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

University of Pennsylvania

Watch author

Derived topics and classifications

psilocybin Addiction Brain Imaging Mechanism of Action Other

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive SymptomsClinicalTrials.gov · 2026-07-01 Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)Cognitive MechanismsClinicalTrials.gov · 2024-08-07 A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of PsilocybinClinicalTrials.gov · 2026-07-17 Psilocybin for Treatment of Obsessive Compulsive DisorderClinicalTrials.gov · 2026-05-12 An international mega-analysis of psychedelic drug effects on brain circuit function.Nature medicine · 2026-04-01 Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive DisorderClinicalTrials.gov · 2025-11-26 PRoMiSS: Psilocybin and the Role of Music in Set and SettingClinicalTrials.gov · 2025-09-18 Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)ClinicalTrials.gov · 2026-07-09